

MedChemWatch

The official EFMC e-newsletter

2

July 2007

IN THIS ISSUE

1 | EDITORIAL

2 | PERSPECTIVE

Innovative Medicines Initiative is on the way to be fully operative by the beginning of 2008

4 | LAB PRESENTATION

The Collegium Helveticum Zürich

6 | SCHOOL

LACDR School on Medicinal Chemistry, Leiden

7 | COMMITTEES

News from EFMC Committees

9 | GRANT ALERT

Second FTP calls

10 | EFMC MEETINGS

Conference report

Vth Austrian-German-Hungarian-Italian-Polish-Slovenian Joint Meeting (JMMC)
Portorož, June 17-21, 2007

Joint ASMC meeting

St Petersburg, August 27-31, 2007

11 | EFMC NEWS

EFMC welcomes two new member societies

12 | CALENDAR OF EVENTS

Editorial



Dear Colleague,

thank you very much for all the positive feedback to MedChemWatch, the official EFMC e-newsletter! We hope that it fulfils your need and you consider it a valuable source of information. In this issue we would like to draw your attention to the Innovative Medicine Initiative, which has excellent chances to become operative at the beginning of the year 2008. With this public-private partnership the European Commission together with major European Pharmaceutical Companies will invest 2 billion to overcome current bottlenecks in the drug discovery and development process. You will also find a short report from the Council Meeting, which was held in June in Portoroz. I am pleased to announce that the Council welcomed two new member societies, the Section for Medicinal Chemistry of the German Pharmaceutical Society and the Medicinal Chemistry Group of the Portuguese Chemical Society. The lab presentation will highlight the Collegium Helveticum, ETH Zuerich, a truly interdisciplinary institution.

Last but not least I would like to encourage you to register on our web-page www.efmc.info. This will ensure that we are using the correct E-mail address and also help to enhance our database. In the near future we will steadily work on increasing our services, which will be accessible for registered users only. I hope you enjoy this issue and wish you a recreative summer breake.

Gerhard Ecker
Editor



EFMC
European Federation
for Medicinal Chemistry

Perspective

Innovative Medicines Initiative is on the way to be fully operative by the beginning of 2008

BY FERRAN SANZ

On last May 21-22, the European Commission presented to the Competitiveness Council a formal proposal for creating the first two **Joint Technology Initiatives (JTI)**, one of them being the **Innovative Medicines Initiative (IMI)**. It is expected that the consultation to the European Parliament and the final approval by the Competitiveness Council will happen during the second semester of 2007, in time for IMI to start work early in 2008. *JTIs are a new instrument of the 7th Framework Programme.* They will run as joint undertakings under article 171 of the EC treaty.

Innovative Medicines Initiative, a joint undertaking of the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA) will support the development of new knowledge, tools and methods so that better and safer medicines can be made available more quickly. The IMI seeks to overcome research bottlenecks in the drug discovery and development process. Its vision is to create real European leadership in biomedical research and development and thereby reinvigorate the European biopharmaceuticals sector, making Europe a more attractive destination for private R&D investment in this sector. The IMI will embody a new approach to research financing at the European


level, bringing together public and private funds.

The programme will have €2 billion to invest over seven years. The pharmaceutical companies will contribute with €1 billion by paying the totality of the cost of their participation in the projects, whilst the European Community contribution of other €1 billion will go entirely to SMEs and non-profit research institutions. The IMI will therefore contribute to increasing private investment in R&D, improving the knowledge transfer between European academic, clinical and industrial

organisations.

IMI's goal is not the development of new medicines as such but the development of methods and tools that facilitate to bring new safe and effective medicines to market as quickly as possible.

IMI's strategic research agenda (SRA) is focused on four areas: improved predictivity of safety evaluation, improved predictivity of efficacy evaluation, knowledge management, and education and training (see <http://www.imi-europe.org/>).



If we look the SRA from our perspective as medicinal chemists, it is obvious that the chemical perspective of the pharmaceutical R&D has not been explicitly recognised as one of the IMI's priority areas, maybe because chemistry is the central field for the competition between pharmaceutical companies and not a field for their cooperation as pretended in IMI. Nevertheless, a careful reading of the SRA offers interesting niches for making significant chemical contributions to

the future projects. For instance, a better understanding of the disease mechanisms is one of the key issues of such agenda and the design of relevant chemical probes can be particularly useful for this purpose. On the other hand, the development of in silico methods for the pre-clinical prediction of drug safety, another key topic of the SRA, requires a clear chemical background.

In summary, in the next years we are going to see how IMI becomes a cru-

cial initiative for setting priorities in pharmaceutical R&D and for funding collaborative projects in the area. In consequence, IMI deserves to be followed with pro-active attention by all the professionals involved in the drug discovery and development pipeline from both industry and academia. ■

LAB PRESENTATION

The Collegium Helveticum Zürich

BY GERD FOLKERS

“We hypothesize that changes in role identity can be induced in clinical settings as well. The mechanisms of action of the observed results remain uncertain, but new treatments for pain conditions, which modulate self-perceived role identity in emotionally meaningful settings, may contribute to a beneficial influence on pain management.”¹

Where is the link to medicinal chemistry?

Very likely, the subjects who changed their role identity during the experiment and were able to bear considerable more pain, produced more endogenous opioids and more of its receptors to interfere with the pain signal. While there is no doubt about a ligand – receptor interaction at the end of the chain, the detailed processes underlying the observation remain unclear, especially for the role of perception and emotion. Hence, this simple experiment raises a number of questions in and adjacent to medicinal chemistry which we try to answer in a rather unusual setting of a “laboratory for interdisciplinarity”, the Collegium Helveticum in Zürich.

History

Being a forum of dialogue between the sciences, Collegium Helveticum was founded by the ETH Zurich in 1997, with the objective of promoting a more in-depth discourse of natural and technical sciences with humanities and social sciences.

Interdisciplinary and transdisciplinary dialogue, and exchange of ideas between natural and technical sciences with humanities, art and medical science are still core and vision of the Collegium.

Mission

The Collegium Helveticum perceives transdisciplinarity as an indispensable element of its research projects. These projects are carried out with cooperation of the University of Zurich and the ETH Zurich as well as other academies, research institutes and industry partners, under the direction of Collegium Helveticum. Within the interdisciplinary and transdisciplinary research Collegium pursues



Information and contact

Read more about people, projects and publications on our webpage

<http://www.collegium.ethz.ch/index.en.html>

or contact gerd.folkers@collegium.ethz.ch

¹ *Changes in Self-Perceived Role Identity Modulate Pain Perception*, Elvan Kut, Nils Schaffner, Amrei Wittwer, Victor Candia, Meike Brockmann, Claudio Storck & Gerd Folkers, DOI: 10.1016/j.pain.2007.04.012

a pragmatic approach based on cooperation, communication and coordination. Disciplinary competence has thereby always been a prerequisite.

Collegium Helveticum as a research institute is committed to a bottom-up-approach. Together with interested scientists (fellows) and invited institutions that are endowed with complex questions that are in need of interdisciplinary approaches, one or several joint research projects are designed combining several fields.

Collegium Helveticum is not an introversive institution. It initiates and organizes symposiums, lectures, workshops and other events which are all interdisciplinary and public. In this manner, Collegium tries to bring together diverse subgroups in order to promote the interchange of ideas between students, scientists and representatives from arts, economics, literature and the public, and it acts as a catalyst in relevant questions of the present and the future.

Structure

“Fellows” are professors of the ETH Zurich and University of Zurich and are elected by a curatorium (the rectors of the two institutions and the president of the Swiss Academy of Sciences) for a 5 years period in which they serve for 20% share of their time at the Collegium and are equivalently reimbursed by their home institutions. “Affiliated Fellows” are researchers from either universities or public institutions or the industry, who spent a certain amount of the time at the Collegium according to their interest or that of their home institutions.

The director of the Collegium is elected by the curatorium for a period of 5 year and is a professor at ETH Zurich or University of Zurich. For the period until 2009 Prof. Dr. Gerd Folkers has taken the responsibility to head the Collegium Helveticum.

Research

The Fellows, the affiliated Fellows and the director are expected to take part in the academic life of both home institutions in research and teaching. Usually the Conference of the Fellows chooses one research topic to focus on for the whole period, resulting in a multidisciplinary and hopefully transdisciplinary research project. At the moment, a group of experts from the fields of Chemistry, History, Environmental Sciences, Medical Science, Neurosciences, Economics, Pharmacy and Religious Philosophy deals with the current research topic entitled «The role of an emotion: its contribution to human acts and in establishing social and behavioral norms».

Actually the Collegium hosts 6 Fellows, 3 affiliated Fellows, 15 senior researchers or post docs and 17 PhD students from various disciplines.

Teaching

Biweekly public lectures and student lectures given by the Fellows and invited experts parallel the research project, thus providing a wide spectrum of views on the topic of research for both the public and the students. Regular inhouse research colloquia for all members of the Collegium deepen the understanding and foster interdisciplinary discussion and dissemination of the ideas. In the monthly fellows meeting, reports are discussed to develop further research strategies.

Achievements

After having collaborated for half of the period now, all the members of the Collegium have acquired and improved abilities in exchanging their disciplinary views and concepts with other disciplines. Re-formulation and re-evaluation of hypotheses have led to common interdisciplinary research proposals to the National Science Foundation and foreign science agencies. Open-minded dialogue between disciplines, listening

and learning and flat hierarchies have been established as essentials of research culture at the Collegium Helveticum. ■

For further information on EFMC approved schools, please visit www.efmc.info

LACDR School on Medicinal Chemistry


BY AD P. IJZERMAN

Ever since 1992 the Leiden/Amsterdam Center for Drug Research has organized its annual School on Medicinal Chemistry. It has been shown to fulfill a clear need within the pharmaceutical industry of training their newly hired chemists. “What happens to your molecule” has always been the leading theme within the four days of teaching. The School offers a thorough background in anything that affects the fate of a medicinal chemistry program, from the selection and validation of novel drug targets, to the pharmacologic and toxicological follow-up of compounds.

Thus, the course provides a thorough introduction in pharmacodynamics, pharmacokinetics and toxicology (ADME-Tox). The impact of molecular biology, genomics and computational chemistry on drug research are also discussed. Of course, new developments are carefully integrated in the course. As an example, fragment-based design approaches were recently introduced. Highly appreciated are the “case histories”. Over the years our evening program has highlighted success stories from the pharmaceutical industry, with an open eye for trial and error, opportunities and sheer ‘luck’ when it comes to the full development of lead candidates into marketed drugs.

Henk Timmerman and Ad IJzerman have been the course directors from the very beginning, joined by Rob Leurs

starting this year. Critical to the success of the School have been the excellent teachers, a careful mix of colleagues from industry and academia. We insisted on them being teachers – at least for the four days of the course – rather than excellent scientists presenting their latest but rather exotic data. All participants are asked to rate the contributions, and it is fair to say



that on the basis of the participants’ recommendations we have not hesitated to search for substitutes. As mentioned, an additional flavour to the course are the case histories, which are presented by the ‘inventors’, those of us who have been intimately involved in the conception and further development of the drug of choice. Over the years we have had excellent accounts on taxol, citalopram, omeprazole, imatinib, etc. The course is structured in a very interactive way. Next to discussions following the lectures participants are asked to join a case study, in which a

disease strategy, such as cholesterol-lowering, is taken as the starting point. Before the course starts, relevant literature is distributed to all participants, to allow a comprehensive update on such a topic before the actual course starts. After a further introduction at the course the participants sit together in small groups, discuss and present a number of issues, such as emerging new targets in this disease area. For this reason we keep the number of participants, mostly young chemists from the pharmaceutical industry, rather low, i.e. a maximum of 35.

The 2007 course, the 16th in a row, will take place in Noordwijkerhout, the Netherlands, (close to Amsterdam airport), from October 16-19.

You are very much invited to join the course, and have a great experience. Acclaim has been great over the years, e.g., excellent documentation...; case-study very useful....; very clear review of drug research today....; lectures very good....; beyond expectation....; intellectually most stimulating....; first class facilities.

Just contact Mrs Martha van der Ham (m.ham@lacdr.leidenuniv.nl), and she will make sure to update you on the contents of this year’s course and the registration details. ■

NEWS FROM EFMC COMMITTEES

One of the main strategic initiatives of EFMC was the establishment of the four Committees approved at the Council meeting in Istanbul 2006:

Education & Training Committee (ETC) – Chair: *Péter Mátyus*

European Commission R&D Initiatives Committee (ECIC) – Chair: *Ferran Sanz*

Industry Liaison Committee (ILC) – Chair: *Brigitte Lesur*

Information & Communication Committee (ICC) – Chair: *Gerhard Ecker*

At the Council meeting in Portoroz all four Committee chairs gave updates on the activities of their Committees:

Education and Training Committee (ETC)

PÉTER MÁTYUS (*Chair*)

The Committee organised several round table discussions on the future of Medicinal Chemistry Teaching & Training in Europe.

The ETC will also discuss and propose a definition of Medicinal Chemistry. Another main activity is the generation of a compendium on existing undergraduate and postgraduate level training courses within Europe. For this a questionnaire on 'Teaching and Training in Medicinal Chemistry' was sent to all EFMC council members late 2006. Unfortunately the response was not overwhelming, so there is still the possibility to provide baseline information from your country. If you wish to contribute to this project please contact Henk Timmerman at henktim@planet.nl. A report will be prepared by end of the year and published in the newsletter.

ETC would welcome your knowledge, experience and ideas.

If you wish to contribute towards our objectives, please contact:

peter.matyus@szerves.sote.hu

Industry Liaison Committee (ILC)

BRIGITTE LESUR (*Chair*)

Current main activity is the acquisition of corporate Sponsors in order to

get formalised contacts to Industry. Additionally, the Council established a working group which will develop a concept for Short Courses on special topics in Medicinal Chemistry especially useful for participants from Industry. Head of the group is Peter Etmayer, Boehringer Ingelheim, Austria.

ILC would welcome your knowledge, experience and ideas.

If you wish to contribute towards our objectives, please contact:

blesur@fr.netgrs.com

European Commission R&D Initiatives Committee (ECIC)

FERRAN SANZ (*Chair*)

The main goal of the Committee is to improve and strengthen the contacts of EFMC to the European Commission in order to increase the visibility of EFMC and its activities. In addition, the ECIC will also act as a forum for discussing and promoting R&D initiatives important for Medicinal Chemistry in Europe. Currently the Committee is heavily involved in the discussions around the Innovative Medicines Initiative (see also the perspective in this issue). The final decision on the structure, organisation and budget should be made by end of the year and first calls will be launched in early 2008.

ECIC would welcome your knowledge, experience and ideas.

If you wish to contribute towards our

Within this chapter we will give regular updates on the activities of our Committees.

objectives, please contact:
fsanz@imim.es

Information & Communication Committee (ICC)

GERHARD ECKER (*Chair*)

The main activity of the Information & Communication Committee was the establishment of MedChemWatch – the official EFMC e-newsletter (www.efmc.info/medchemwatch). This was a huge effort and highly appreciated by the community. In Portoroz several proposals for further improvements have been made, such as including a section for presentations of SMEs and book reports. Furthermore, with the next issue we will start a series on the History of EFMC, written by Henk Timmerman.

Next priorities of the ICC will be the restructuring of the Web-page in order to make informations on our activities more readily available. Furthermore, we are actively working on a concept for a job-database and on the possibility for providing abstracts of our sponsored meetings and teaching material from our Medicinal Chemistry Schools to Corporate Members and Member Societies.

ICC would welcome your knowledge, experience and ideas.

If you wish to contribute towards our objectives, please contact:

gerhard.fecker@univie.ac.at ■

Seventh Research Framework Programme

BY JORDI MESTRES

Second call

deadline 18 September 2007

HEALTH-2007-2.3.1-1

Novel targets for drugs against Gram negative bacteria. The objective is to identify and validate novel drug targets in order to select lead compounds, which may be derived from natural resource or from synthetic compounds, for future development of a new class of anti-infective drugs against Gram negative bacteria.

HEALTH-2007-2.3.4-3

Bioprospecting for drug leads. The project will collect, isolate and investigate potential drug leads from terrestrial and marine biodiversity sources. The aim is to build/enhance libraries of biological compounds that can be tested as drug leads for a variety of infectious diseases (e.g. virostatica, antihelminthic or antimycoplasmic compounds). The project must respect international agreements on sustainable use of biodiversity and equitable benefit sharing and include work packages on IPR and other legal issues of access and use of those compounds.

HEALTH-2007-2.4.3-6

Nutritional signals and the development of new diabetes/obesity therapeutic agents.

This project will focus on the effects of alternative compounds which improve carbohydrate/lipid metabolism or modify body weight, and could be used in the development of new therapeutics in the treatment of hyperglycemia and hyperlipidemia.

.....

In this edition of the EFMC Newsletter, we will recall the Health topics in the second call of the FP7 (http://cordis.europa.eu/fp7/cooperation/health_en.html) that may require medicinal chemistry efforts and also alert on a call from the European Science Foundation aiming at funding Research Networking Programmes (<http://www.esf.org/activities/research-networking-programmes.html>).

.....

ESF call

deadline 30 October 2007:

Research Networking Programmes. These are networking activities aimed at bringing together nationally funded research activities for 4 to 5 years, to address a major scientific issue or a science-driven topic of research infrastructure, at the European level with the aim of advancing the frontiers of science. ■

EFMC MEETINGS

In 2007, EFMC is involved in three major Medicinal Chemistry Events in Europe. The Austrian-German-Hungarian-Italian-Polish-Slovenian Joint Meeting on Medicinal Chemistry, the ASMC 07 meeting in St. Petersburg and last but not least the first event jointly organised by the ACS-Division of Medicinal Chemistry and EFMC, which will take place in October in Siena.



Advances in Synthetic and Medicinal Chemistry

August 27-31, 2007, St. Petersburg, Russia

For information: <http://wwwasmc07.org>



Frontiers in CNS and Oncology Medicinal Chemistry

October 7-9, 2007 Siena, Italy

For information: <http://www.acsefmc-italy2007.it>



American Chemical Society 234th National Meeting & Exposition

August 19-23, 2007 Boston, MA USA

For information: <http://acswebcontent.acs.org/nationalmeeting/boston2007/home.html>



Austrian_German_Hungarian_Italian_Polish_Slovenian

5th Joint Meeting on Medicinal Chemistry

June 17-21, 2007, Portorož, Slovenia

CONFERENCE REPORT

5th Austrian-German-Hungarian-Italian-Polish-Slovenian Joint Meeting on Medicinal Chemistry (JMMC)

Portorož, August 29-September 2, 2006

BY ALEŠ OBREZA AND LUCIJA PETERLIN MAŠIČ

In June 2007 the 5th Joint Meeting on Medicinal Chemistry was organized by the Medicinal Chemistry Section of the Slovenian Pharmaceutical Society under the auspices of the European Federation of Medicinal Chemistry. The symposium took place in Portorož, in the Slovenian Adriatic coast, where the clean sea and the majestic Alps come close to an embrace.

It continued the tradition of previous joint meetings held in Italy (Taormina 1999), Hungary (Budapest 2001), Poland (Krakow 2003) and Austria (Vienna 2005). The 5th Joint Meeting on Medicinal Chemistry focused on important new developments in the following topics: anti-infectives, drugs for cardiovascular and metabolic disorders, enzymes and receptors as targets for new drugs, computer-aided drug design and discovery, emerging strategies in drug discovery, and medicinal chemistry case studies.

The inaugural plenary lecture was delivered by the Nobel laureate Prof. Robert Huber who opened the event with his interesting talk, entitled Proteins and Their Structures in Basic Science and Medicine in which he presented the complex role of proteins in living organisms, their dynamic nature and the role of X-ray crystallography in the identification of 3D-structure of macromolecules. The scientific programme comprised seven plenary



The JMMC team

lectures, twenty keynote lectures, fifteen oral communications and 172 poster presentations (<http://www.jmmc2007.si>) and was supplemented with a rich social programme in one of the most popular congress and vacation resorts in Slovenia. We are pleased that many students participated in this event which allowed young scientists to meet established medicinal chemists for exciting exchange of ideas in the latest advances in drug discovery and development.

In summary, the 5th Joint Meeting on Medicinal Chemistry in Portorož 2007 was a scientifically and socially very rewarding event, providing an opportunity for more than 300 participants from 31 countries worldwide for the exchange of scientific information and for establishing personal contacts. At the end, the members of the organizing committee wish a successful organization to our successors for the 6th JMMC, which will take place in Sicily in 2009. ■

EFMC welcomes two new member societies

BY GERHARD ECKER

In 2006, the European Federation for Medicinal Chemistry represented 21 scientific organisations from 19 European countries. This year, at the annual meeting held in Portorož, the Council of EFMC unanimously accepted the application of two new members, the Section for Pharmaceutical/Medicinal Chemistry, German Pharmaceutical Society, and the Medicinal Chemistry Group, Portuguese Chemical Society. Becoming a member of EFMC requires a formal application which is first discussed within the Executive Committee. If granted by the EC, the application is put on the agenda of the next ordinary Council meeting, where the final decision is made. Main criteria to be considered are the activities of the applicants in the field of Medicinal Chemistry and their legal status as Scientific Organisation within the European Sphere.

At the Council meeting also several other major decisions have been adopted:

Gerhard Ecker, Univ. Vienna and currently Secretary of EFMC, was elected to President elect for the year 2008. Subsequently he will serve as President of EFMC in the years 2009-2011.

The **Council** unanimously approved several changes in the regulations which guarantee, that both Industry and Academia is represented in the Executive Committee. Furthermore, the Committees have been formalised and are now an integral part of the organisation and management of the Federation.

A **new financial framework** for the organisation of the International

The **Section of Pharmaceutical/Medicinal Chemistry of the German Pharmaceutical Society**, represented by Prof. Gerhard Klebe, is well established and has about 700 members comprising mainly scientists from Pharmaceutical Institutes and Academia. Main activities include the organisation of scientific events, donation of prizes and supporting the education and training, particular for Pharmacy students.




The **Group of Medicinal Chemistry of the Portuguese Chemical Society** has recently been created and was represented by Prof. Luisa Sa e Melo and Prof. Rui Moreira. The group is steadily growing and currently comprises already more than 60 members. Starting with the successful meeting "Medicinal Chemistry in the 21st Century" in Lisbon, Oct 2006, the group will organise further events and also expressed its interests to get in touch with our Teaching & Training Committee.

Symposium of Medicinal Chemistry was introduced, which allows EFMC a more reasonable participation on the financial benefits of our flagship event.

The **Web-site** now offers the possibility to indicate whether you are a member of one of the EFMC Member Societies. This is a further step towards creating direct benefit for scientists who are members of our National Adhering Organisations. Please have a look and register today (www.efmc.info), then go to "register"!

The Call for the three **EFMC Awards** will be launched in autumn 2007: the Nauta Award for Pharmacochimistry, the UCB Award for Excellence in

Medicinal Chemistry and the Prous Science Award for New Technologies in Drug Discovery. Please be prepared to send us your nominations!

The EFMC-sponsored session at the 234th ACS National Meeting in Boston, Aug 19-23, (www.chemistry.org) is organised by Roberto Pellicciari and will focus on "*Treatment of Cerebral Ischemia: Recent Therapeutic Strategies*". The detailed program and the abstracts of the talks can be found at our web-page: (www.efmc.info) ■

American Chemical Society 234th National Meeting & Exposition

August 19-23, 2007

Boston, USA

Web: <http://www.chemistry.org/portal/a/c/s/1/acdisplay.html?DOC=meetings\national\overview.html>

The program of the EFMC sponsored session as well as the abstracts can be found at our web-page www.efmc.info

Advances in Synthetic and Medicinal Chemistry

August 27-31, 2007

St. Petersburg, Russia

Web: <http://www.asmc07.org>

16th Camerino Noordwijkerhout Symposium: an overview of Receptor Chemistry

September 9-13, 2007

Camerino, Italy

Web: <http://www.unicam.it/farmacia/symposium/index.html>

XVIIIth National Meeting of the Medicinal Chemistry Division

September, 16-20, 2007

Chieti, Italy

Web: <http://www.chimfarm2007.unich.it>

Summer School on Drug Design

September 16-21, 2007

Vienna, Austria

Web: <http://www.oephg.at>

Frontiers in CNS and Oncology Medicinal Chemistry

October 7-9, 2007

Siena, Italy

Web: <http://www.acsefmc-italy2007.it/home.htm>

16th LACDR School on Medicinal Chemistry

October 16-19, 2007

Nordwijkerhout, The Netherlands

E-mail: m.ham@lacdrleidenuniv.nl

3rd International Meeting on Medicinal and Pharmaceutical Chemistry

October 16-21, 2007

WOW Kremlin Palace/Antalya

Web: <http://www.immpc-3.org>

New Drugs and Drug Candidates: Recent Achievements in Medicinal Chemistry - Annual One Day Meeting on Medicinal Chemistry of SRC & KVCV

October 26, 2007

UCB, Braine-l'Alleud, Belgium

<http://www.medchem.be>

Satelite in Sopron

Metabolic Disorders. From Bench to Bedside A satellite Symposium of the XXth ISMC

August 28-31, 2008

Sopron, Hungary

Web: <http://www.metdis2008.mke.org.hu>

XXth International Symposium on Medicinal Chemistry

August 31 – September 4, 2008

Vienna, Austria

Web: <http://www.ismc.2008.org>

XIXth National Meeting on Medicinal Chemistry

September 14-18, 2008

Verona, Italy

E-mail: mosti@unige.it

XXIst International Symposium on Medicinal Chemistry

August, 2010

Brussels, Belgium

edmond.differding@ucb-group.com

MedChemWatch no. 2 July 2007

Editor

Gerhard F. Ecker *Univ. Vienna, AT*

Editorial Committee

Koen Augustyns *Univ. Antwerpen, BE*

Erden Banoglu *Gazi Univ., TR*

Gabriele Costantino *Univ. Parma, IT*

Jordi Mestres *IMIM-UPF, ES*

Kristian Strømgaard *Univ. Copenhagen, DK*

Design

Pupilla grafik

www.pupilla.eu

Web Design

Antalys Sprl

www.antalys.be



EFMC

European Federation for Medicinal Chemistry

www.efmc.info

info@efmc.info

Executive Committee

Roberto Pellicciari *President*

Ferran Sanz *Past-President*

Gerhard F. Ecker *Secretary*

Rasmus P. Clausen *Treasurer*

David Alker *Member*

Brigitte Lesur *Member*

Péter Mátyus *Member*